Athersys, Inc. (ATHXQ)

Market Cap	62.00
Revenue (ttm)	80.00K
Net Income (ttm)	-37.51M
Shares Out	61.75M
EPS (ttm)	-1.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	713
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Athersys

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrom...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 24
• Stock Exchange: OTCMKTS
• Ticker Symbol: ATHXQ

Financial Performance

In 2022, Athersys's revenue was $5.33 million, a decrease of -3.43% compared to the previous year's $5.51 million. Losses were -$72.53 million, -16.58% less than in 2021.